The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•14 April 2026•

1 min read

TriSalus Life Sciences to Showcase PEDD Platform Data at SIR 2026

Key Facts

1TriSalus Life Sciences (TLSI) will present new clinical and preclinical data at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting.

2The presentations will highlight the capabilities of the Pressure Enabled Drug Delivery (PEDD) platform for liver-directed therapies and uterine artery embolization.

3The data aims to demonstrate the platform's versatility in enhancing therapeutic delivery across various disease states.

TriSalus Life Sciences (TLSI) announced its participation in the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting, where it will present new clinical and preclinical data. The presentations will focus on the capabilities of the company's proprietary Pressure Enabled Drug Delivery (PEDD) platform, specifically regarding liver-directed therapies and uterine artery embolization. This data aims to demonstrate the platform's versatility in enhancing therapeutic delivery across various complex disease states. By showcasing these findings, TriSalus intends to highlight the growing body of evidence supporting its technology's potential to significantly improve patient outcomes. Investors typically view such scientific presentations as critical milestones for validating a biotech company's long-term clinical pipeline. The upcoming event underscores the company's commitment to advancing medical device innovation within the oncology and interventional radiology sectors.